Saihe Medical raises hundreds of millions yuan in Series B+ for pan-vascular smart diagnosis and treatment products
Hardware
Originally reported by 投资界 (PEdaily)
Saihe Medical (Shenzhen Saihe Medical Technology Co., Ltd.) has closed a Series B+ financing round totaling hundreds of millions of yuan (approximately $28-42 million USD), led by Yafu Investment and Stelco Capital, with follow-on participation from existing shareholder Furong Investment. The company, headquartered in Shenzhen, China, focuses on active interventional devices for pan-vascular diseases including coronary artery disease, peripheral vascular disease, structural heart disease, heart failure, and intracranial vascular conditions. CEO Liu Bin stated the funds will accelerate R&D registration, supply chain construction, and global commercialization of core product pipelines, particularly in shockwave and intravascular ultrasound technologies.
This funding round is significant for the medical device segment of additive manufacturing, as Saihe Medical's core products rely on advanced manufacturing techniques including precision micro-machining and laser-based fabrication for catheter-based interventional tools. The company positions itself as a domestic alternative to foreign-dominated technologies in active interventional diagnosis and treatment, a space where AM enables complex geometries in guidewires, balloons, and ultrasound transducers. The pan-vascular active intervention market in China is growing rapidly, driven by aging demographics and increasing prevalence of cardiovascular disease, with domestic substitution policies accelerating adoption. Saihe's platform approach, combining shockwave lithotripsy and intravascular ultrasound, mirrors the strategy of global leaders like Shockwave Medical and Boston Scientific, but with a focus on cost-effective, locally manufactured solutions.
From an AM industry perspective, Saihe Medical's progress underscores the growing role of precision manufacturing in medical devices beyond orthopedic implants. The company's success depends on scaling production while maintaining regulatory compliance across multiple geographies, particularly as it moves from clinical validation to commercial rollout. Investors should watch for CE marking and NMPA registration timelines for its lead products, as these will determine revenue trajectory. The round also signals continued investor appetite for Chinese medtech companies that combine hardware innovation with domestic supply chain advantages, a pattern consistent with broader localization trends in advanced manufacturing.
Topics